tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2022 Oct;28(13):238-243.
doi: 10.3201/eid2813.212477.
Effectiveness of Whole-Virus COVID-19 Vaccine among Healthcare Personnel, Lima, Peru
Carmen S Arriola, Giselle Soto, Matthew Westercamp, Susan Bollinger, Angelica Espinoza, Max Grogl, Alejandro Llanos-Cuentas, Eduardo Matos, Candice Romero, Maria Silva, Rachel Smith, Natalie Olson, Michael Prouty, Eduardo Azziz-Baumgartner, Fernanda C Lessa
Abstract
In February 2021, Peru launched a COVID-19 vaccination campaign among healthcare personnel using an inactivated whole-virus vaccine. The manufacturer recommended 2 vaccine doses 21 days apart. We evaluated vaccine effectiveness among an existing multiyear influenza vaccine cohort at 2 hospitals in Lima. We analyzed data on 290 participants followed during February-May 2021. Participants completed a baseline questionnaire and provided weekly self-collected nasal swab samples; samples were tested by real-time reverse transcription PCR. Median participant follow-up was 2 (range 1-11) weeks. We performed multivariable logistic regression and adjusted for preselected characteristics. During the study, 25 (9%) participants tested SARS-CoV-2-positive. We estimated adjusted vaccine effectiveness at 95% (95% CI 70%-99%) among fully vaccinated participants and 100% (95% CI 88%-100%) among partially vaccinated participants. These data can inform the use and acceptance of inactivated whole-virus vaccine and support vaccination efforts in the region.
Keywords: COVID-19; Peru; SARS; SARS-CoV-2; coronavirus; coronavirus disease; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccines; viruses; zoonoses.
. 2022 Oct;28(13):238-243.
doi: 10.3201/eid2813.212477.
Effectiveness of Whole-Virus COVID-19 Vaccine among Healthcare Personnel, Lima, Peru
Carmen S Arriola, Giselle Soto, Matthew Westercamp, Susan Bollinger, Angelica Espinoza, Max Grogl, Alejandro Llanos-Cuentas, Eduardo Matos, Candice Romero, Maria Silva, Rachel Smith, Natalie Olson, Michael Prouty, Eduardo Azziz-Baumgartner, Fernanda C Lessa
- PMID: 36502444
- DOI: 10.3201/eid2813.212477
Abstract
In February 2021, Peru launched a COVID-19 vaccination campaign among healthcare personnel using an inactivated whole-virus vaccine. The manufacturer recommended 2 vaccine doses 21 days apart. We evaluated vaccine effectiveness among an existing multiyear influenza vaccine cohort at 2 hospitals in Lima. We analyzed data on 290 participants followed during February-May 2021. Participants completed a baseline questionnaire and provided weekly self-collected nasal swab samples; samples were tested by real-time reverse transcription PCR. Median participant follow-up was 2 (range 1-11) weeks. We performed multivariable logistic regression and adjusted for preselected characteristics. During the study, 25 (9%) participants tested SARS-CoV-2-positive. We estimated adjusted vaccine effectiveness at 95% (95% CI 70%-99%) among fully vaccinated participants and 100% (95% CI 88%-100%) among partially vaccinated participants. These data can inform the use and acceptance of inactivated whole-virus vaccine and support vaccination efforts in the region.
Keywords: COVID-19; Peru; SARS; SARS-CoV-2; coronavirus; coronavirus disease; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccines; viruses; zoonoses.